Publicación Oficial de la Sociedad Ecuatoriana de Neurología, de la Liga Ecuatoriana Contra la Epilepsia y de la Sociedad Iberoamericana de Enfermedad Cerebrovascular

tolerabilidad

 

Carbamazepina y Valproato de Magnesio en el tratamiento de la Epilepsia del Lóbulo Temporal Mesial de debut.

Introduction: Mesial Temporal Lobe Epilepsy is the most frequent symptomatic focal epilepsy in adults. There are no prospective studies that compare the efficacy and effectiveness of carbamazepine and valproic acid in this group of patients.

Objective: to compare the efficacy, effectiveness and tolerability of Carbamazepine and Valproic Acid in patients with Mesial Temporal Lobe Epilepsy.

Methods: We conducted a prospective, controlled and randomized study of parallel groups in patients with Mesial Temporal Lobe Epilepsy at time of onset. The patients were followed-up for one year. Fifty six patients were recruited. Forty three patients participated in a crossover study and only thirty three concluded it. We evaluated the efficacy, effectiveness and tolerability of two antiepileptic drugs.

Results: After cross-over, the efficacy of Valproic Acid was superior to Carbamazepine reducing seizure frequency from 7,9 to 2,6 seizures per month (p = 0,02). None of antiepilpetic drugs were associated with an improvement in Hamilton scale. Treatment with valproic Acid improved the quality of life by 20 % after a year of treatment (p < 0,01) . The number of patients with side effects was not significant statistically, even though valproic acid produced a greater variety of adverse effects.

Conclusion: The effectiveness and efficacy of Valproic Acid in patients with mesial Temporal Lobe Epilpesy at onset is superior to carbamazepine althought it is less tolerated.

Leer artículo completo

 
 
Licencia Creative Commons
Salvo que se estipule lo contrario el contenido de la Revista Ecuatoriana de Neurología está bajo una Licencia Creative Commons Atribución-NoComercial-SinDerivadas 4.0 Internacional.